Y-mAbs Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Y-mAbs Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q3 2024.
  • Y-mAbs Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$8.57M, a 10.6% decline year-over-year.
  • Y-mAbs Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$28.5M, a 20.5% decline year-over-year.
  • Y-mAbs Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$25.7M, a 72.9% increase from 2022.
  • Y-mAbs Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$94.8M, a 17.9% increase from 2021.
  • Y-mAbs Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$115M, a 3.75% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$28.5M -$8.57M -$819K -10.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-08
Q2 2024 -$27.6M -$9.79M -$2.57M -35.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 -$25.1M -$6.91M +$593K +7.91% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$25.7M -$3.2M -$2.05M -177% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 -$23.6M -$7.75M +$18.3M +70.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-08
Q2 2023 -$41.9M -$7.22M +$32.7M +81.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 -$74.6M -$7.5M +$20.2M +72.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$94.8M -$1.15M +$34.6M +96.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 -$129M -$26M +$2.69M +9.36% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$132M -$39.9M -$17.2M -75.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$115M -$27.7M +$564K +2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 -$115M -$35.8M -$15.7M -77.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$99.8M -$28.7M +$3.94M +12.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$104M -$22.7M +$17.7M +43.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$121M -$28.3M -$1.51M -5.65% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$120M -$20.1M +$3.66M +15.4% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 -$124M -$32.6M -$8.28M -34% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$115M -$40.5M -$21.8M -117% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$93.5M -$26.7M -$10.5M -64.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$83M -$23.8M -$9.68M -68.8% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$73.3M -$24.4M -$12.9M -113% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 -$60.4M -$18.6M -$8.38M -81.7% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 -$52M -$16.3M -$8.77M -117% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 -$43.2M -$14.1M -$4.8M -51.8% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$38.4M -$11.4M -$7.57M -197% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-12
Q2 2018 -$30.9M -$10.3M -$7.03M -218% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-12
Q1 2018 -$23.8M -$7.48M -$4.58M -158% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-12
Q4 2017 -$19.2M -$9.28M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-22
Q3 2017 -$3.84M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-22
Q2 2017 -$3.23M Apr 1, 2017 Jun 30, 2017 10-K 2019-03-22
Q1 2017 -$2.9M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.